A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

106 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-01-31

Study Completion Date

2005-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will look at whether this new drug is effective in the treatment of rheumatoid arthritis, and at whether it is safe and well-tolerated by participants with the disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008)

NCT00542022

Arthritis, Rheumatoid

COMPLETED PHASE2

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)

NCT01651936

Rheumatoid Arthritis

TERMINATED PHASE2

Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)

NCT00482417

Rheumatoid Arthritis

COMPLETED PHASE2

Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis

NCT01038674

Inflammation Rheumatoid Arthritis

COMPLETED PHASE1

A Phase I Rheumatoid Arthritis Study in Healthy Volunteers

NCT00539760

Arthritis, Rheumatoid

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MK-0873

MK-0873 1.25 mg twice daily for 12 weeks

Group Type EXPERIMENTAL

MK-0873

Intervention Type DRUG

MK-0873 1.25 mg twice daily for 12 weeks

Placebo

Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks

Group Type PLACEBO_COMPARATOR

Comparator: Placebo

Intervention Type DRUG

Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK-0873

MK-0873 1.25 mg twice daily for 12 weeks

Intervention Type DRUG

Comparator: Placebo

Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Rheumatoid arthritis, according to the American College of Rheumatology criteria, with active disease despite current medications
* Other criteria also apply